Global Soft Tissue Sarcoma Market Size study & Forecast, by Treatment, By Route of Administration, By End-users, and Regional Analysis, 2023-2030

Description

List of Tables

Global Soft Tissue Sarcoma Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, nerves, blood vessels, and connective tissues. A lump or swelling in a body's soft tissue is an indication of soft tissue sarcoma. There are many different locations on the body where soft tissue sarcomas develop, which is identified through biopsy. The global market growth is driven by factors such as the rising adoption of novel therapies, growing focus on personalized medicine, escalating population, and increasing healthcare expenditure, coupled with favorable reimbursement policies.

In addition, the surge in the incidences of cancer is acting as a catalyzing factor for market growth across the globe. According to the World Health Organization, in 2020, it was estimated that around 19.3 million new cancer cases were recorded globally, which is projected to increase and likely to reach 30.3 million cases by the year 2040. Thus, these aforementioned factors are propelling the growth of the soft tissue sarcoma market during the estimated period. Moreover, the rising advancements in diagnostics and treatment options, as well as increasing investments in research and development is presenting various lucrative opportunities over the forecasting years. However, the high cost of treatments and the side effects of soft tissue sarcoma drugs are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Soft Tissue Sarcoma Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surging demand for targeted therapies, rising focus on personalized medicine, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of soft tissue sarcoma, increasing healthcare expenditure, and growing investments in research and development.

Major market players included in this report are:

F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GSK plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Merck & Co., Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)

Recent Developments in the Market:

In 2019, Pfizer announced that Vitrakvi (larotrectinib) had received European Commission approval for the treatment of advanced soft tissue sarcoma. Vitrakvi - a targeted medication is available to patients whose tumours have a particular genetic mutation.
In 2019, Johnson & Johnson declared that the US Food and Drug Administration had authorized JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is developed for use in the treatment of several malignancies, including some types of sarcomas.

Global Soft Tissue Sarcoma Market Report Scope:

Historical Data: - 2020 - 2021
Base Year for Estimation: - 2022
Forecast period: - 2023-2030
Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: - Treatment, Route of Administration, End-users, Region
Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment:

Targeted Therapy
Chemotherapy
Anti-Angiogenesis Drugs
Radiation Therapy

By Route of Administration:

Oral
Parenteral
Others

By End-users:

Hospitals
Homecare
Speciality Centres
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Chapter 1. Executive Summary

1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Soft Tissue Sarcoma Market, by Region, 2020-2030 (USD Billion)
- 1.2.2. Soft Tissue Sarcoma Market, by Treatment, 2020-2030 (USD Billion)
- 1.2.3. Soft Tissue Sarcoma Market, by Route of Administration, 2020-2030 (USD Billion)
- 1.2.4. Soft Tissue Sarcoma Market, by End-users, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption

Chapter 2. Global Soft Tissue Sarcoma Market Definition and Scope

2.1. Objective of the Study
2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

Chapter 3. Global Soft Tissue Sarcoma Market Dynamics

3.1. Soft Tissue Sarcoma Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
  - 3.1.1.1. Rising adoption of novel therapies
  - 3.1.1.2. Surge in the incidences of cancer
- 3.1.2. Market Challenges
  - 3.1.2.1. High cost of treatments
  - 3.1.2.2. Side effects of soft tissue sarcoma drugs
- 3.1.3. Market Opportunities
  - 3.1.3.1. Rising advancements in diagnostics and treatment options
  - 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Soft Tissue Sarcoma Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Impact Analysis
4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Soft Tissue Sarcoma Market, by Treatment

5.1. Market Snapshot
5.2. Global Soft Tissue Sarcoma Market by Treatment, Performance - Potential Analysis
5.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
5.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
- 5.4.1. Targeted Therapy
- 5.4.2. Chemotherapy
- 5.4.3. Anti-Angiogenesis Drugs
- 5.4.4. Radiation Therapy

Chapter 6. Global Soft Tissue Sarcoma Market, by Route of Administration

6.1. Market Snapshot
6.2. Global Soft Tissue Sarcoma Market by Route of Administration, Performance - Potential Analysis
6.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
6.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
- 6.4.1. Oral
- 6.4.2. Parenteral
- 6.4.3. Others

Chapter 7. Global Soft Tissue Sarcoma Market, by End-users

7.1. Market Snapshot
7.2. Global Soft Tissue Sarcoma Market by End-users, Performance - Potential Analysis
7.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by End-users 2020-2030 (USD Billion)
7.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
- 7.4.1. Hospitals
- 7.4.2. Homecare
- 7.4.3. Speciality Centres
- 7.4.4. Others

Chapter 8. Global Soft Tissue Sarcoma Market, Regional Analysis

8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Soft Tissue Sarcoma Market, Regional Market Snapshot
8.4. North America Soft Tissue Sarcoma Market
- 8.4.1. U.S. Soft Tissue Sarcoma Market
  - 8.4.1.1. Treatment breakdown estimates & forecasts, 2020-2030
  - 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
  - 8.4.1.3. End-users breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Soft Tissue Sarcoma Market
8.5. Europe Soft Tissue Sarcoma Market Snapshot
- 8.5.1. U.K. Soft Tissue Sarcoma Market
- 8.5.2. Germany Soft Tissue Sarcoma Market
- 8.5.3. France Soft Tissue Sarcoma Market
- 8.5.4. Spain Soft Tissue Sarcoma Market
- 8.5.5. Italy Soft Tissue Sarcoma Market
- 8.5.6. Rest of Europe Soft Tissue Sarcoma Market
8.6. Asia-Pacific Soft Tissue Sarcoma Market Snapshot
- 8.6.1. China Soft Tissue Sarcoma Market
- 8.6.2. India Soft Tissue Sarcoma Market
- 8.6.3. Japan Soft Tissue Sarcoma Market
- 8.6.4. Australia Soft Tissue Sarcoma Market
- 8.6.5. South Korea Soft Tissue Sarcoma Market
- 8.6.6. Rest of Asia Pacific Soft Tissue Sarcoma Market
8.7. Latin America Soft Tissue Sarcoma Market Snapshot
- 8.7.1. Brazil Soft Tissue Sarcoma Market
- 8.7.2. Mexico Soft Tissue Sarcoma Market
8.8. Middle East & Africa Soft Tissue Sarcoma Market
- 8.8.1. Saudi Arabia Soft Tissue Sarcoma Market
- 8.8.2. South Africa Soft Tissue Sarcoma Market
- 8.8.3. Rest of Middle East & Africa Soft Tissue Sarcoma Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. F. Hoffmann-La Roche Ltd. (Switzerland)
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Recent Developments
- 9.3.2. Mylan N.V. (U.S.)
- 9.3.3. Teva Pharmaceutical Industries Ltd. (Israel)
- 9.3.4. Sanofi (France)
- 9.3.5. Pfizer Inc. (U.S.)
- 9.3.6. GSK plc (U.K.)
- 9.3.7. Novartis AG (Switzerland)
- 9.3.8. Bayer AG (Germany)
- 9.3.9. Merck & Co., Inc. (U.S.)
- 9.3.10. Sun Pharmaceutical Industries Ltd. (India)

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption

LIST OF TABLES

TABLE 1. Global Soft Tissue Sarcoma Market, report scope
TABLE 2. Global Soft Tissue Sarcoma Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Soft Tissue Sarcoma Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
TABLE 4. Global Soft Tissue Sarcoma Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
TABLE 5. Global Soft Tissue Sarcoma Market estimates & forecasts by End-users 2020-2030 (USD Billion)
TABLE 6. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Soft Tissue Sarcoma Market
TABLE 71. List of primary sources, used in the study of global Soft Tissue Sarcoma Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

FIG 1. Global Soft Tissue Sarcoma Market, research methodology
FIG 2. Global Soft Tissue Sarcoma Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Soft Tissue Sarcoma Market, key trends 2022
FIG 5. Global Soft Tissue Sarcoma Market, growth prospects 2023-2030
FIG 6. Global Soft Tissue Sarcoma Market, porters 5 force model
FIG 7. Global Soft Tissue Sarcoma Market, pest analysis
FIG 8. Global Soft Tissue Sarcoma Market, value chain analysis
FIG 9. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Soft Tissue Sarcoma Market, regional snapshot 2020 & 2030
FIG 15. North America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
FIG 16. Europe Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)